New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:23 EDTBMYBristol-Myers acquires iPerian for $175M
Bristol-Myers Squibb and iPierian announced Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies. The acquisition gives Bristol-Myers Squibb full rights to iPierian’s asset IPN007, a preclinical monoclonal antibody that represents a new approach to treat progressive supranuclear palsy and other Tauopathies, and has the potential to commence Phase 1 clinical trials by early FY15. Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierian’s issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175M, with the potential for additional development and regulatory milestone payments totaling $550M, along with future royalties on net sales. The transaction is expected to be accounted for as an asset acquisition for Bristol-Myers Squibb resulting in a $175M charge during 2Q14.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
17:23 EDTBMYBristol-Myers gets FDA approval for Evotaz to treat HIV-1 infections
Subscribe for More Information
08:14 EDTBMYCelldex, Bristol-Myers initiate Phase 1/2 Varlilumab, Opdivo combination study
Subscribe for More Information
January 27, 2015
07:37 EDTBMYBristol-Myers sees FY15 EPS $1.55-$1.70, consensus $1.71
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q4 EPS 46c, consensus 41c
Subscribe for More Information
January 26, 2015
15:40 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
11:29 EDTBMYBristol-Myers January weekly volatility increases into Q4 and outlook
Subscribe for More Information
January 22, 2015
08:49 EDTBMYBristol-Myers price target raised to $70 from $63 at SunTrust
Subscribe for More Information
January 21, 2015
10:16 EDTBMYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:34 EDTBMYBristol-Myers appoints Giovanni Caforio CEO
Bristol-Myers Squibb announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May. Giovanni Caforio, M.D. will become CEO of the company. Lamberto Andreotti will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3. James M. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. Togo D. West, Jr., 72, will become the lead independent director on the company’s board.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use